OakChart

Gain Therapeutics Inc

GANXHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.11+0.03 (2.78%)
2026-11-11 22:51 CET
Market cap
47.14 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-17.98 USD m
Free cash flow, TTM
-17.07 USD m
EPS diluted, TTM
-0.43
P/E
-
Compare

Price

GANX against its 20, 50 and 200-day averages
2050200beat
1.001.502.006.3M12.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26GANXclose 1.1120-day 1.1650-day 1.50200-day 1.821.1152w low

74.4% under the 52-week high of 4.34 on 11 Dec 2025. 52-week low 0.94 on 5 Nov 2026. Last 15 sessions, 42.9% high to low

Volume 0.58× normal · the line is the 50-bar volume average

Profile

GANX
52-week range, 5% of the way up
0.944.34

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Employees21
IPOMar 18, 2021
Beta0.30
ATR, 14d0.10
Rel volume0.58
Short float9.19%
Insider own2.93%
Inst own20.14%

Snapshot

6 groups

Valuation

Index-
Market Cap48.45M
Enterprise Value37.43M
Income-17.98M
Sales0.00M
Book/sh0.23
Cash/sh0.27
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees21
IPOMar 18, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B4.85
P/C4.14
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio5.36
Current Ratio5.36
Debt/Eq0.07
LT Debt/Eq0.04
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.43
EPS next Y-0.63
EPS next Q-0.12
EPS this Y22.62%
EPS next Y-33.47%
EPS next 5Y-3.43%
EPS past 3/5Y25.52% -15.21%
Sales past 3/5Y- -
EPS Y/Y TTM33.17%
Sales Y/Y TTM-
EPS Q/Q52.19%
Sales Q/Q-
EarningsNov 10 BMO
EPS/Sales Surpr.43.82% -

Ownership

Insider Own2.93%
Insider Trans0.00%
Inst Own20.14%
Inst Trans1.06%
ROA-148.59%
ROE-223.94%
ROIC-170.37%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-4.58%
SMA50-25.84%
SMA200-39.15%
Trades-

Technical

Shs Outstand44.32M
Shs Float42.36M
Short Float9.19%
Short Ratio7.68
Short Interest3.89M
52W High4.34 -74.42%
52W Low0.94 18.07%
Volatility12.08% 9.52%
ATR (14)0.10
RSI (14)37.80
Beta0.30
Rel Volume0.58
Avg Volume506.83K
Volume291,871

Performance

Perf Week0.00%
Perf Month-21.28%
Perf Quarter-48.73%
Perf Half Y-37.64%
Perf YTD-65.53%
Perf Year-58.58%
Perf 3Y-59.49%
Perf 5Y-85.16%
Perf 10Y-
Recom1.00
Target Price7.20
Prev Close1.08
Price1.11
Change %2.78%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Mar 07, 2025InitiatedBScotiabankSector Outperform$12+981.1%
Dec 06, 2024InitiatedRROTH MKMBuy$7+530.6%
Aug 14, 2024ResumedOOppenheimerOutperform$8+620.7%
Apr 12, 2021InitiatedOOppenheimerOutperform$30+2,602.7%
Apr 12, 2021InitiatedBBTIG ResearchBuy$30+2,602.7%

Peers

Mkt cap
TickerCompanyMkt cap
DNLIDenali Therapeutics Inc3.16B
ATHEAlterity Therapeutics Ltd ADR44.12M
VYGRVoyager Therapeutics Inc109.53M
ANVSAnnovis Bio Inc36.41M
PASGPassage Bio Inc12.87M
CGTXCognition Therapeutics Inc64.42M
PMNProMIS Neurosciences Inc33.72M
ACETAdicet Bio Inc27.99M
SUPNSupernus Inc6.12B
AMRXAmneal Pharmaceuticals Inc7.56B

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 200
  • Gain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update (GlobeNewswire)
  • Gain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences (GlobeNewswire) -13.48%
  • Gain Therapeutics to Attend the 2026 Maxim Growth Summit (GlobeNewswire)
  • Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration (GlobeNewswire)
  • Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson's Disease and Movement Disorders (GlobeNewswire) -5.08%
  • Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference (GlobeNewswire)
  • Gain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update (GlobeNewswire) +16.38%
  • Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update (GlobeNewswire)
  • Why Is GANX Stock Rallying 22% After Hours? (Stocktwits) +13.14%
  • Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson's Disease (GlobeNewswire)
  • Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit (GlobeNewswire)
  • Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026 (GlobeNewswire)
  • Gain Therapeutics (GANX) Shares Edge Higher After Narrower-Than-Expected Q1 Loss (InvestorsHub)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-10-0.070-0.125-0.0700.000.005
2026Q22026-08-11-0.110-0.138-0.1090.000.005
2026Q12026-05-11-0.130-0.138-0.1330.000.004
2025Q42026-03-26-0.110-0.144-0.1130.000.005
2025Q32025-11-12-0.150-0.161-0.1510.000.005
2025Q22025-08-12-0.190-0.167-0.1920.000.006
2025Q12025-05-14-0.160-0.180-0.1580.000.035
2024Q42025-03-27-0.080-0.184-0.1390.000.006
2024Q32024-11-14-0.170-0.207-0.1690.000.015
2024Q22024-08-08-0.420-0.195-0.4240.000.404
2024Q12024-05-14-0.220-0.311-0.2230.000.125
2023Q42024-03-27-0.290-0.312-0.2920.000.255
2023Q32023-11-14-0.370-0.446-0.3720.000.345
2023Q22023-08-10-0.620-0.308-0.6210.001.014
2023Q12023-05-12-0.430-0.394-0.4300.060.013
2022Q42023-03-23-0.390-0.365-0.3930.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY-0.892--0.3010.03-
2021FY-1.370-1.574-1.3670.170.15
2022FY-1.480-1.412-1.4800.140.13
2023FY-1.710-1.600-1.7110.060.28
2024FY-0.890-0.964-0.8920.000.00
2025FY-0.610-0.644-0.6110.000.00
2026FY--0.472--0.00
2027FY--0.630--0.00
2028FY--0.675--0.00
2029FY-0.320--51.21
2030FY-1.680--134.57

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-103000.000.000.00
2026Q4S2026-08-113000.000.000.00
2026Q4S2026-05-273000.000.000.00
2026Q4S2026-05-112000.000.000.00
2026Q4S2026-04-191000.000.000.00
2026Q4S2026-03-262000.000.000.00
2026Q4S2026-01-222000.000.000.00
2026Q4S2025-11-282010.000.000.00
2026Q4S2025-11-121000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4R2026-11-10210-0.11-0.11-0.10
2026Q4R2026-10-27200-0.14-0.16-0.11
2026Q4R2026-10-25210-0.14-0.16-0.11

Estimate history

EPS, annual-0.093-0.185-0.301-1.367-1.48-1.711-0.892-0.612-0.4272
Period20182019202020212022202320242025TTM
EPS, quarterly-0.169-0.139-0.158-0.192-0.151-0.113-0.133-0.109-0.072
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0.0210.0410.0290.1650.140.055000
Period20182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual-11.87611.87611.88311.88316.20727.13342.07444.324
Period20182019202020212022202320242025MRQ
Shares, quarterly25.96227.13328.74630.77135.97642.07442.48943.34144.324
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.060.140.160.030.040.02
Cost of Goods Sold Incl. D&A0.090.090.080.080.06----
Gross Profit-0.09-0.09-0.08-0.030.08----
Selling, General and Administrative Excl. Other17.6118.6220.2722.2317.8513.983.502.141.05
Research and Development8.6210.1710.7511.498.357.152.251.580.83
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-17.70-18.71-20.35-22.25-17.78-13.83-3.48-2.10-1.03
Interest Expense-------0.020.05
Unusual Expense0.000.000.000.000.000.000.000.000.00
Net Income Before Taxes-17.55-19.30-19.87-22.19-17.50-13.89-3.57-2.19-1.10
Income Taxes0.430.860.540.080.090.000.010.010.01
Consolidated Net Income-17.98-20.16-20.41-22.27-17.59-13.89-3.58-2.19-1.11
Net Income From Continuing Operations-17.98-20.16-20.41-22.27-17.59-13.89-3.58-2.19-1.11
Net Income-17.98-20.16-20.41-22.27-17.59-13.89-3.58-2.19-1.11
EPS (Recurring)-0.41-0.61-0.89-1.71-1.48-1.37-0.30-0.18-0.09
EPS (Basic, Before Extraordinaries)-0.43-0.61-0.89-1.71-1.48-1.37-0.30-0.18-0.09
EPS (Diluted)-0.43-0.61-0.89-1.71-1.48-1.37-0.30-0.18-0.09
EBITDA-17.61-18.62-20.27-22.17-17.71-13.81-3.47-2.10-1.03
Non-Operating Income (Expense)0.15-0.590.480.060.28-0.06-0.09-0.07-0.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.381.421.892.571.210.610.080.000.00
Price To Sales Ratio---769.88265.47334.55---
Gross Margin----45.6754.20----
Operating Margin----40,328.26-12,688.10-8,379.80-12,047.54-5,084.89-4,989.66
Net Margin----40,354.33-12,555.13-8,418.86-12,387.67-5,310.88-5,364.36
Shares Outstanding44.3242.0727.1316.2111.8811.8811.8811.88-
Market Capitalization47.1447.1457.2966.7937.2064.5162.96--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.020.030.020.030.020.020.020.02
Gross Profit-0.02-0.03-0.02-0.03-0.02-0.02-0.02-0.02
Selling, General and Administrative Excl. Other3.184.655.334.444.765.074.353.31
Research and Development1.412.122.752.332.842.752.251.21
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-3.20-4.68-5.35-4.47-4.79-5.09-4.37-3.33
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-3.09-4.57-5.43-4.47-4.74-5.67-4.43-3.26
Income Taxes0.070.100.180.070.550.140.100.50
Consolidated Net Income-3.16-4.68-5.61-4.54-5.28-5.81-4.53-3.77
Net Income From Continuing Operations-3.16-4.68-5.61-4.54-5.28-5.81-4.53-3.77
Net Income-3.16-4.68-5.61-4.54-5.28-5.81-4.53-3.77
EPS (Recurring)-0.07-0.11-0.13-0.11-0.15-0.19-0.16-0.14
EPS (Basic, Before Extraordinaries)-0.07-0.11-0.13-0.11-0.15-0.19-0.16-0.14
EPS (Diluted)-0.07-0.11-0.13-0.11-0.15-0.19-0.16-0.14
EBITDA-3.18-4.65-5.33-4.44-4.76-5.07-4.35-3.31
Non-Operating Income (Expense)0.120.11-0.07-0.000.05-0.58-0.060.07
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.300.450.320.320.360.410.330.28
Shares Outstanding44.3243.3442.4942.0735.9830.7728.7527.13
Market Capitalization47.1486.5981.95123.8563.6353.9050.6657.29

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments20.8410.3916.7920.1436.887.500.30-
Short Term Receivables0.800.770.240.190.200.070.04-
Inventories0.000.000.000.000.000.000.00-
Other Current Assets0.600.450.740.760.650.070.05-
Total Current Assets22.2411.6017.7821.0937.727.640.40-
Net Property, Plant & Equipment0.410.320.590.801.010.550.22-
Total Investments and Advances0.040.030.031.970.030.000.01-
Intangible Assets0.100.130.190.210.20-0.00-
Other Assets0.030.030.020.020.021.410.03-
Total Assets22.8212.1218.6124.1038.999.600.66-
Short Term Debt Incl. Current Port. of LT Debt0.220.270.350.340.320.150.10-
Accounts Payable0.830.951.321.630.560.960.15-
Income Tax Payable0.040.020.050.110.000.000.00-
Other Current Liabilities2.262.683.232.051.671.010.62-
Total Current Liabilities3.353.914.954.132.552.110.88-
Long Term Debt0.510.380.680.941.291.120.10-
Provision for Risks Charges0.390.440.310.160.330.170.13-
Other Liabilities0.000.050.090.000.000.000.01-
Total Liabilities4.254.786.035.224.173.401.11-
Non-Equity Reserves0.000.000.000.000.000.000.00-
Preferred Stock - Carrying Value0.000.000.000.000.000.000.00-
Common Equity18.567.3412.5818.8834.826.20-0.45-
Total Shareholders Equity18.567.3412.5818.8834.826.20-0.45-
Accumulated Minority Interest0.000.000.000.000.000.000.00-
Total Equity18.567.3412.5818.8834.826.20-0.45-
Total Liabilities & Stockholders Equity22.8212.1218.6124.1038.999.600.66-
Book Value Per Share0.440.270.781.592.930.52-0.04-
Tangible Book Value Per Share0.440.270.761.572.910.52-0.04-
Full-Time Employees212532322514--
Price to Book Ratio4.726.295.691.641.851.68--
Return on Assets-115.39-132.83-104.28-55.77-57.18-69.71--
Return on Equity-155.66-204.95-141.57-65.52-67.73-124.39--
Return on Invested Capital-105.69-264.34-167.97-88.77-38.47-48.89--
Quick Ratio6.632.973.595.1114.783.610.45-
Current Ratio6.632.973.595.1114.783.610.45-

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-17.98-20.16-20.41-22.27-17.59-13.89-3.58-2.19-1.11
Depreciation0.100.090.080.080.060.020.010.000.00
Other Funds (Non Cash)2.032.612.532.881.321.840.090.010.04
Funds from Operations-15.86-17.46-17.79-19.31-16.21-12.04-3.48-2.18-1.06
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.22-1.01-1.080.441.51-0.330.240.310.32
Income Taxes Payable---0.120.010.060.06-0.00-0.010.01
Cash from Operating Activities-17.07-18.47-18.87-18.87-14.69-12.37-3.24-1.87-0.74
Capital Expenditures0.000.00-0.02-0.02-0.12-0.09-0.02-0.01-0.01
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.005.0010.24-14.660.000.000.000.00
Purchase of Investments0.000.000.00-1.96-17.740.000.000.000.00
Sale Or Maturity of Investments0.000.005.0012.193.080.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities0.000.004.9810.22-14.77-0.09-0.02-0.01-0.01
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock20.1828.5413.3812.730.0042.649.751.750.00
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock20.1828.5413.3812.730.0042.649.751.750.00
Proceedsfrom Stock Options0.00-0.400.000.000.0042.639.751.750.00
Issuance or Reduction of Debt, Net-0.10-0.10-0.09-0.09-0.08-0.020.740.000.98
Change in Long Term Debt-0.10-0.10-0.09-0.09-0.08-0.020.740.000.98
Issuance of Long Term Debt0.000.000.000.000.000.000.740.000.98
Reduction of Long Term Debt-0.10-0.10-0.09-0.09-0.08-0.020.000.000.00
Net Financing Active Other Cash Flow0.000.00-0.280.000.00-0.850.000.000.00
Other Financing Activities Uses0.000.00-0.280.000.00-0.850.000.000.00
Cash from Financing Activities20.0828.4513.0112.64-0.0841.7710.491.750.98
Exchange Rate Effect-0.110.47-0.530.49-0.020.10-0.040.030.01
Net Change in Cash2.8910.46-1.414.49-29.5729.417.19-0.100.24
Free Cash Flow-17.07-18.47-18.90-18.88-14.81-12.46-3.26-1.88-0.75
Preferred Dividends (Cash Flow)-0.000.000.000.000.00--0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments11.7013.0816.5420.848.816.69
Short Term Receivables0.311.030.990.800.791.41
Inventories0.000.000.000.000.000.00
Other Current Assets0.690.850.690.600.921.20
Total Current Assets12.7014.9718.2222.2410.529.31
Net Property, Plant & Equipment0.410.310.360.410.270.33
Total Investments and Advances0.030.040.040.040.040.04
Intangible Assets0.070.080.090.100.110.13
Other Assets0.030.030.040.030.030.03
Total Assets13.2315.4218.7422.8210.979.83
Short Term Debt Incl. Current Port. of LT Debt0.270.230.220.220.240.26
Accounts Payable0.601.221.520.831.582.71
Income Tax Payable0.040.070.070.040.050.03
Other Current Liabilities1.451.912.092.262.312.20
Total Current Liabilities2.373.433.893.354.175.20
Long Term Debt0.400.380.460.510.360.42
Provision for Risks Charges0.310.320.390.390.530.52
Other Liabilities0.000.000.000.000.000.00
Total Liabilities3.084.134.734.255.066.14
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity10.1511.2914.0118.565.913.70
Total Shareholders Equity10.1511.2914.0118.565.913.70
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity10.1511.2914.0118.565.913.70
Total Liabilities & Stockholders Equity13.2315.4218.7422.8210.979.83
Book Value Per Share0.230.260.330.440.160.12
Tangible Book Value Per Share0.230.260.330.440.160.12
Full-Time Employees---21--
Price to Book Ratio4.726.164.4019.6014.748.95
Return on Assets-148.59-159.22-139.91-115.39-153.07-128.09
Return on Equity-223.94-268.30-214.69-155.66-261.72-240.21
Return on Invested Capital-29.94-40.07-38.78-23.79-84.24-141.19
Quick Ratio5.364.364.696.632.521.79
Current Ratio5.364.364.696.632.521.79

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-3.16-4.68-5.61-4.54-5.28-5.81
Depreciation0.020.030.020.030.020.02
Other Funds (Non Cash)0.320.670.630.410.471.20
Funds from Operations-2.82-3.98-4.95-4.10-4.79-4.59
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-0.22-0.700.23-0.52-0.14-0.51
Cash from Operating Activities-3.05-4.68-4.73-4.62-4.93-5.10
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.781.390.4316.587.062.49
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.781.390.4316.587.062.49
Proceedsfrom Stock Options0.000.000.000.00-0.400.00
Issuance or Reduction of Debt, Net-0.02-0.03-0.03-0.03-0.02-0.02
Change in Long Term Debt0.000.000.00-0.100.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-0.100.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.751.370.4016.557.032.47
Exchange Rate Effect-0.09-0.140.020.100.010.26
Net Change in Cash-1.39-3.46-4.3012.032.11-2.37
Free Cash Flow-3.05-4.68-4.73-4.62-4.93-5.10

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.19%3.9M42.4M500.85K
2026-10-157.53%3.2M42.4M467.39K
2026-09-307.21%3.1M42.4M529.07K
2026-09-156.82%2.9M42.4M765.68K
2026-08-316.60%2.8M42.4M813.20K
2026-08-146.97%3.0M42.3M890.59K
2026-07-317.77%3.2M41.4M861.19K
2026-07-158.67%3.6M41.4M878.60K
2026-06-308.72%3.6M41.4M820.85K
2026-06-159.35%3.9M41.4M642.63K
2026-05-297.73%3.2M41.4M668.57K
2026-05-157.64%3.2M41.4M673.03K
2026-04-308.32%3.4M41.4M689.53K
2026-04-158.16%3.3M40.8M733.11K
2026-03-318.04%3.3M40.8M863.05K
2026-03-137.74%2.9M37.2M1.22M
2026-02-277.76%2.9M37.2M1.31M
2026-02-138.18%3.0M37.2M1.33M
2026-01-308.01%3.0M37.2M1.49M
2026-01-156.68%2.5M37.2M1.45M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.350.900.6313.51340113.000.924-0.0190.000
call1.000.050.500.1316.4924372370.907-0.0270.000
call1.500.001.000.2217.9179990.000.901-0.0310.000
call2.000.000.150.055.0921,5791800.365-0.0190.001
call3.000.000.300.056.48125311.000.320-0.0230.001
call4.000.000.050.035.33330.000.000.145-0.0110.000
call5.000.000.400.056.0579.002.000.134-0.0130.000
call6.000.001.000.806.35610.000.000.130-0.0120.000
put0.500.001.000.240.0005.000.000.0000.0000.000
put1.000.001.000.100.0001.000.00-0.194-0.0250.000
put1.500.101.100.5012.0131,1060.00-0.099-0.0300.000
put2.000.501.500.7511.3331,0530.00-0.635-0.0190.001
put3.001.502.500.0012.7840.000.00-0.679-0.0230.001
put4.002.403.400.0012.1170.000.00-0.855-0.0110.000
put5.003.404.403.4712.7750.000.00-0.864-0.0110.000
put6.004.405.400.0013.2920.000.00-0.870-0.0120.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-108-KCurrent report2026-11-10SEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-29SEC
2026-10-303Initial statement of beneficial ownership of securities2026-10-28SEC
2026-10-288-KCurrent report2026-10-22SEC
2026-10-018-KCurrent report2026-10-01SEC
2026-09-288-KCurrent report2026-09-22SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-174Statement of changes in beneficial ownership of securities2026-07-15SEC
2026-07-168-KCurrent report2026-07-16SEC
2026-06-298-KCurrent report2026-06-29SEC
2026-06-258-KCurrent report2026-06-24SEC
2026-05-268-KCurrent report2026-05-26SEC
2026-05-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-118-KCurrent report2026-05-11SEC
2026-04-28ARSAnnual report to security holders. 2025-12-31SEC
2026-04-28DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-28DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-24SEC
2026-03-264Statement of changes in beneficial ownership of securities2026-03-24SEC
2026-03-264Statement of changes in beneficial ownership of securities2026-03-24SEC
2026-03-2610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-268-KCurrent report2026-03-26SEC
2026-03-188-KCurrent report2026-03-18SEC
2026-02-038-KCurrent report2026-02-03SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MARSHALL WACE, LLP4.51%
Potomac Capital Management, Inc.2.22%
GSA CAPITAL PARTNERS LLP1.48%
JONES FINANCIAL COMPANIES LLLP1.43%
DME Capital Management, LP1.33%
Cambridge Investment Research Advisors, Inc.1.30%
VANGUARD CAPITAL MANAGEMENT LLC1.13%
GEODE CAPITAL MANAGEMENT, LLC1.08%
BlackRock, Inc.0.64%
UBS Group AG0.55%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND1.01%
Fidelity Extended Market Index Fund0.51%
iShares Micro-Cap ETF0.34%
Fidelity Total Market Index Fund0.15%
Fidelity Series Total Market Index Fund0.15%
Ultra-Small Company Market Fund0.07%
Fidelity Nasdaq Composite Index Fund0.05%
1290 VT Micro Cap Portfolio0.02%
Victory Extended Market Index Fund0.01%
iShares Neuroscience and Healthcare ETF0.00%

OakChart. GANX. Cached 15 minutes.

Some panels did not load: insider.